On November 3, the National Science and Technology Awards Conference of 2020 was grandly held in the Great Hall of the People in Beijing. The project of "Key Technology and Industrialization of Lipid Nanomedicine Preparations for Intravenous Injection" with the core participation of YaoPharma won the second prize of National Science and Technology Progress Award. The project has innovated the key technologies for the preparation and industrialization of nano-medicine preparations, solved thebottleneck problem in the development of nano-medicine preparations, promoted the industrialization and clinical application of nano-medicine preparations, and promoted the overall development of nano-medicine preparations. YaoPharma has successfully applied the results to a cardio-cerebral vascular product-Alprostadil Dry Emulsion for Injection.

It is reported that the National Science and Technology Progress Award is one of the five national science and technology awards established by the State Council. It is mainly awarded to Chinese citizens and organizations who have made creative contributions in the process of technological research, technological development, technological innovation, promotion and application of advanced scientific and technological achievements, promotion of high-tech industrialization, and completion of major scientific and technological projects and plans. Totally 264 projects were selected for the National Science and Technology Awards of 2020, including 137 second-class National Science and Technology Progress Awards.

Related Links

↓ ​↓ ​↓

Generic name: Alprostadil dried emulsion for injection

Alprostadil dried emulsion for injection ( 优帝尔 ®, Chinese Pinyin: Youdier) is the world's first dry emulsion for injection. It is a national key new product and a national patent product. It has a clear target to improve microcirculation and stabilize blood rheology. This product not only adopts advanced "lipid microsphere carrier targeting technology", and also has an exclusive "nano formulation freeze-drying protection technology", which can protect the lipid microsphere structure from demulsification; the quality standard is strict, and the PGA1 limit is 10%, which is only 1/6 of the regular alprostadil injection, which improves the stability and safety of the drug. This product is also the only Alprostadil targeted preparation that does not require cold chain transportation and refrigeration. A major breakthrough has been made in storage conditions. It only needs to be stored in a cool place (<20°C) and is not afraid of freezing, effectively reducing storage risks and solving hospital cold chain drug storage problems.